Business Context and Reporting Period
This Form 6-K filing by GlaxoSmithKline plc covers the period ending April 23, 2008. The report details a specific corporate action regarding the repurchase and cancellation of the Company's own ordinary shares, executed in accordance with shareholder authority granted at the Annual General Meeting on May 23, 2007.
Key Financial Metrics
The filing does not provide standard financial performance metrics such as revenue, profit, cash flow, margins, debt, or liquidity. The document focuses exclusively on share capital transactions.
- Shares Repurchased: 2,150,000 ordinary shares of 25 pence each.
- Repurchase Price: 1,112.94 pence per share.
- Treasury Shares Held: 484,194,158 shares (representing 9.00% of total voting rights).
- Shares in Issue: 5,382,342,163 shares (excluding Treasury shares).
Material Changes
The primary material change reported is the reduction of the Company's share capital through the cancellation of 2,150,000 repurchased shares. Consequently, the total number of shares in issue was adjusted to 5,382,342,163. The filing does not provide comparative data against prior periods for financial performance.
Guidance, Outlook, and Risks
The filing contains no management commentary, financial guidance, outlook, or discussion of risks and contingencies. It explicitly states that the announcement does not constitute an offer or solicitation to purchase securities and is made in conformity with the Financial Services Authority's Disclosure and Transparency Rules.
Key Facts for Investor Verification
- Verify the total number of shares in issue (5,382,342,163) for accurate calculation of ownership percentages under Disclosure and Transparency Rules.
- Confirm the updated Treasury share count (484,194,158) and its impact on the 9.00% voting rights representation.
- Note that this filing is a notification of a share buyback execution and does not contain quarterly or annual financial results.